The Changing Landscape of
Research and Development
Click each circle to learn more.
New Drug
Approvals
& Launches
Clinical
Development
Pipeline
Modeling Future
Clinical Trial
Productivity
Clinical
Trial Activity
Modeling Future
Clinical Trial
Productivity
Clinical
Trial Activity
Clinical
Development
Pipeline
New Drug
Approvals
& Launches
New Drug Approvals and Launches
59
New
Treatments
2018 brought a record 59 new treatment options to patients and were supported by a diverse range of clinical trial designs.
years
A group of new drugs launched in 2018 took an average of 13.6 years from first patent filing to launch, indicating that translating a scientific breakthrough to a patient treatment remains a slow and risky process.
drugs
patented
66
Emerging biopharma companies patented 66% of the new drugs in 2018 and registered 47% of them.
drugs
registered
%
%
47
13.6
increase in total clinical trials started in 2018,
9
primarily due to many more Phase II studies being initiated, especially in oncology.
Clinical Trial Activity
%
Drug classes
that have seen the largest increase in the number of products in 2018
Oncology
ALS and other degenerative musculoskeletal conditions
Rare GI diseases
Non-narcotic pain treatments
with life science venture capital deals closed, valuing
2x as much as 2013 deal values.
Confidence in scientific innovation grew in 2018
>1,300
>$23 billion,
of the total
R&D pipeline
is accounted for by emerging biopharma companies.
%
70
doubled
has more than
over the past 3 years.
pipeline
Next-Generation
Biotherapeutics
increase in molecules
%
39
in late-stage development from 2013-2018, totaling 2,891 in 2018.
Clinical Development Pipeline
Composite success rate
of clinical development stages (Phase I to regulatory submission) fell to 11.4% in 2018, down from 14.4% in 2017 and below the average of 14.0% in the prior 10 years.
14.4
11.4
2017
2018
Composite progression time
for all drugs from Phase I to regulatory decision has been rising over the past decade, reaching
12.5 years in 2018.
decline in clinical
trial productivity
%
27
as reflected in a composite index that links success rates, trial duration and clinical trial complexity.
productivity improvements
will be yielded by pools of pre-screened patients and biomarkers in oncology, respectively.
yielding 34% average increases
%
34
Biomarkers will have the greatest impact on clinical trial productivity
across therapy areas.
Clinical Trials
that will see the most significant increases in productivity over the next 5 years include:
Oncology
Neurology
Rare Disease
Cardiovascular
%
71
As high as and
%
104
The most significant productivity changes
will occur in
Phase II trials.
Modeling Future Clinical Trial Productivity
